Summary
Highlights
The video introduces the concept of small-cap companies, defining them as stocks with market caps between $250 million and $5 billion. The primary motivation for investing in these companies is their high growth potential and the opportunity to get in early. While they carry higher risk and volatility, for informed investors, the risk can be comparable to larger companies. The video will review Root, Shift4, Oscar, DLocal, Transmedics, and Szle, highlighting their year-to-date performance and future prospects.
Root, an insurtech company with a $1.13 billion market cap, focuses on behavior-based auto insurance pricing, collecting data via phone sensors and aiming to eliminate credit scores. Despite a recent pullback due to profitability being priced in and increased R&D/marketing spend, its competitive advantages include granular data capture, a partnership with Carvana, and the ability to refuse high-risk drivers. The shift towards smart and autonomous vehicles presents a short-term tailwind (safer cars, lower claims) but a long-term headwind (liability shifting to manufacturers), requiring a pivot to fleet product liability. Root is growing quickly and becoming more profitable in a large market.
Oscar Health, valued at just under $4 billion, has seen a 10.3% year-to-date increase. Discussed extensively, particularly regarding the extension of ACA enhanced credits, Oscar has guided for profitability in 2026, even without these subsidies. Despite a high medical loss ratio in Q3 due to morbidity and initial losses, operational efficiency is improving, with SGNA decreasing while revenue grows. Oscar's tech-first approach and AI integration (Oswell powered by OpenAI) allow for faster adaptation and personalized customer service. The company aims for a 5% operating margin and $2.25 EPS by 2027.
Shift4, a payment processing company with a $4.4 billion market cap, is down 40% year to date. Known for its aggressive M&A strategy, including the Global Blue acquisition, it continues to grow both organically and inorganically. Concerns about debt have been addressed by raising new cash to replace convertible debt with senior notes. Despite management changes and higher spending in 2025, recent outlooks show record transaction volumes, stabilizing margins, and 37% subscription revenue growth. Catalysts for 2026 include European expansion, new verticals, and a potential valuation reset as profitability improves.
DLocal, a fintech company primarily operating in Latin America, has a market cap of $4.2 billion and is up 22% year to date. It has shown strong growth with Total Payment Volume (TPV) increasing 59% year-over-year for four consecutive quarters and an impressive 149% retention rate. The company faces macro headwinds like Argentina's volatility, new tariffs in Mexico, and currency devaluation in Egypt, which have led to some market panic. However, DLocal expects TPV growth to outpace take rate losses. Despite volatility, it remains a fast-growing, profitable company in emerging markets.
Szle, a small 'Buy Now Pay Later' fintech company valued at $2.5 billion, is up 61.7% year to date despite recent pullbacks. Similar to Root, its stock experienced a valuation reset and multiple compression due to rapid early growth. Key metrics like Gross Merchandise Volume (GMV) and revenue grew significantly (59% and 67% year-over-year, respectively), and net income was up 73%. Szle is strategically pivoting to subscription-based growth, resulting in higher customer lifetime value. Future plans include obtaining an ILC banking charter to lower capital costs and increase margins, leveraging AI for efficient scaling and enhanced productivity.
Transmedics, with a $4.3 billion market cap, has almost doubled year-to-date, up 91.2%. The company consistently executes well, showing strong revenue and GAAP earnings growth. While it experiences seasonal revenue declines, this is a recurring pattern. The CEO actively buys shares, demonstrating confidence. Transmedics plans to expand into the kidney market by 2027 and aims for 10,000 transplants by 2028, with a target of 30% operating margin. Its unique market position in organ transplants positions it for continued significant growth, with current analyst expectations often being surpassed.